The potential for IgRT to protect against influenza infection depends on the range of antibodies present in the product, and any cross-reactivity between antibodies to different strains of influenza in the population, especially those directed against HA, but also the more conserved surface antigen of neuraminidase, and M protein. Here, MYOM2 is linked to influenza.